BIOMAT Database Logo BIOMAT Database Logo

A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. 1995

B Combes, and R L Carithers, and W C Maddrey, and D Lin, and M F McDonald, and D E Wheeler, and E H Eigenbrodt, and S J Muñoz, and R Rubin, and G Garcia-Tsao
University of Texas Southwestern Medical Center at Dallas 75235-8887, USA.

One hundred fifty-one patients with primary biliary cirrhosis (PBC) grouped into four strata based on entry serum bilirubin ( < 2 mg/dL vs. 2 md/dL or greater) and liver histology (stages I, II vs. stages III, IV-Ludwig criteria) were randomized within each stratum to ursodiol or placebo given in a single dose of 10 to 12 mg/kg at bedtime for 2 years. Placebo- (n = 74) and ursodiol- treated (n = 77) patients were well matched at baseline for demographic and prognostic factors. Ursodiol induced major improvements in biochemical tests of the liver in strata 1 and 2 (entry bilirubin < 2), but had less effect on laboratory tests in patients with entry serum bilirubin of > or +2 (strata 3 and 4). Histology was favorably affected by ursodiol in patients in strata 1 and 2 but not in strata 3 and 4. Ursodiol enrichment in fasting bile obtained at the conclusion of the trail was approximately 40% and comparable in all strata. Thus, differences in ursodiol enrichment of the bile acid pool do not explain better responses of laboratory tests and histology found in patients with less advanced PBC. Patients treated will ursodiol tended to develop a treatment failure less frequently that those who received placebo, particularly in strata 1 and 2 (ursodiol 42%, placebo 60%, P = .078). Development of severe symptoms (fatigue/pruritus) and doubling of serum bilirubin were reduced significantly in ursodiol-treated patients.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008105 Liver Cirrhosis, Biliary FIBROSIS of the hepatic parenchyma due to obstruction of BILE flow (CHOLESTASIS) in the intrahepatic or extrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cholangitis involves the destruction of small intra-hepatic bile ducts and decreased bile secretion. Secondary biliary cholangitis is produced by prolonged obstruction of large intrahepatic or extrahepatic bile ducts from a variety of causes. Biliary Cirrhosis,Biliary Cirrhosis, Primary,Biliary Cirrhosis, Secondary,Cholangitis, Chronic Nonsuppurative Destructive,Liver Cirrhosis, Obstructive,Primary Biliary Cholangitis,Biliary Cirrhosis, Primary, 1,Primary Biliary Cirrhosis,Secondary Biliary Cholangitis,Secondary Biliary Cirrhosis,Biliary Cholangitides, Primary,Biliary Cholangitis, Primary,Biliary Cholangitis, Secondary,Cholangitides, Primary Biliary,Cholangitis, Primary Biliary,Cholangitis, Secondary Biliary,Cirrhosis, Biliary,Cirrhosis, Secondary Biliary,Liver Cirrhoses, Biliary,Obstructive Liver Cirrhosis,Primary Biliary Cholangitides,Secondary Biliary Cholangitides
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001646 Bile An emulsifying agent produced in the LIVER and secreted into the DUODENUM. Its composition includes BILE ACIDS AND SALTS; CHOLESTEROL; and ELECTROLYTES. It aids DIGESTION of fats in the duodenum. Biliary Sludge,Sludge, Biliary

Related Publications

B Combes, and R L Carithers, and W C Maddrey, and D Lin, and M F McDonald, and D E Wheeler, and E H Eigenbrodt, and S J Muñoz, and R Rubin, and G Garcia-Tsao
Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial.
November 1989, Gastroenterology,
B Combes, and R L Carithers, and W C Maddrey, and D Lin, and M F McDonald, and D E Wheeler, and E H Eigenbrodt, and S J Muñoz, and R Rubin, and G Garcia-Tsao
The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis.
May 1994, Hepatology (Baltimore, Md.),
B Combes, and R L Carithers, and W C Maddrey, and D Lin, and M F McDonald, and D E Wheeler, and E H Eigenbrodt, and S J Muñoz, and R Rubin, and G Garcia-Tsao
A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis.
December 1990, Gastroenterologia Japonica,
B Combes, and R L Carithers, and W C Maddrey, and D Lin, and M F McDonald, and D E Wheeler, and E H Eigenbrodt, and S J Muñoz, and R Rubin, and G Garcia-Tsao
Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study.
February 1997, Scandinavian journal of gastroenterology,
B Combes, and R L Carithers, and W C Maddrey, and D Lin, and M F McDonald, and D E Wheeler, and E H Eigenbrodt, and S J Muñoz, and R Rubin, and G Garcia-Tsao
[Combined ursodeoxycholic acid plus colchicine--treatment of primary biliary cirrhosis: results of a placebo-controlled double-blind study].
March 1992, Zeitschrift fur Gastroenterologie,
B Combes, and R L Carithers, and W C Maddrey, and D Lin, and M F McDonald, and D E Wheeler, and E H Eigenbrodt, and S J Muñoz, and R Rubin, and G Garcia-Tsao
A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid.
May 1995, Gastroenterology,
B Combes, and R L Carithers, and W C Maddrey, and D Lin, and M F McDonald, and D E Wheeler, and E H Eigenbrodt, and S J Muñoz, and R Rubin, and G Garcia-Tsao
Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis.
December 2000, Alimentary pharmacology & therapeutics,
B Combes, and R L Carithers, and W C Maddrey, and D Lin, and M F McDonald, and D E Wheeler, and E H Eigenbrodt, and S J Muñoz, and R Rubin, and G Garcia-Tsao
A Double-Blind, Randomized, Placebo-Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease.
August 2023, Movement disorders : official journal of the Movement Disorder Society,
B Combes, and R L Carithers, and W C Maddrey, and D Lin, and M F McDonald, and D E Wheeler, and E H Eigenbrodt, and S J Muñoz, and R Rubin, and G Garcia-Tsao
Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients.
September 2001, Alimentary pharmacology & therapeutics,
B Combes, and R L Carithers, and W C Maddrey, and D Lin, and M F McDonald, and D E Wheeler, and E H Eigenbrodt, and S J Muñoz, and R Rubin, and G Garcia-Tsao
High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial.
August 2010, Hepatology (Baltimore, Md.),
Copied contents to your clipboard!